# Auxly Cannabis Group Inc. (XLY.TO) fundamentals

Data as of 2026-09-08. TSX, Canada. Sector: Healthcare / Pharmaceuticals. Price C$3.18, market value C$328 million.

## Valuation
- **P/E (trailing): 10.3×** (5-yr avg 5.5×, 3-yr avg 5.5×). Auxly Cannabis Group Inc. trades at 10.3× trailing earnings, well above its own five-year average of 5.5×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.8×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.05**. A PEG of 0.05 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.0×**. Each dollar of revenue is priced at 2.0×.
- **Price / book: 24.3×**. The shares trade at 24.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 7.4×**. Enterprise value is 7.4× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 9.6%** (5-yr avg 1.2%). Free cash flow equals 9.6% of the market value, above its five-year average of 1.2%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 9.7%**. The inverse of the P/E: 9.7% of the price is earned each year.

## Profitability
- **Gross margin: 46.2%**. Auxly Cannabis Group Inc. keeps 46.2% of revenue after the direct cost of what it sells.
- **Operating margin: 12.1%**. 12.1% of revenue is left after running the business.
- **Net margin: 27.6%**. 27.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 23.6%**. 23.6% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 7.8%**. Return on all capital, debt included, is 7.8%.
- **Return on assets: 12.0%**. Each dollar of assets produces 12.0% of profit.

## Growth
- **Revenue growth (1 yr): 23.8%** (3-yr 17.0%/yr, 5-yr 26.5%/yr). Revenue grew 23.8% over the last year, against 26.5% a year compounded over five years.
- **EPS growth (1 yr): 294.1%**. Earnings per share rose 294.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.32**. Debt is 0.32 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.5×**. It would take 0.5 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 4.5×**. Operating profit covers interest 4.5× over, a safe margin.
- **Current ratio: 2.20** (quick 1.26). Current assets cover the next year's liabilities 2.20 times.
- **Altman Z-score: 4.20**. A Z-score of 4.20 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Auxly Cannabis Group Inc. does not currently pay a dividend, but it returned 1.7% of its market value through buybacks over the last year.

## Price and momentum
- **Total return (1 yr): 2093.1%** (YTD 2093.1%, 3-mo 1887.5%). The shares are up 2093.1% over twelve months including dividends.
- **From 52-week high: -3.6%** (106.5% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 73**. An RSI of 73 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): -5.45**. Beta of -5.45 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=XLY.TO · Page: https://foliofundamentals.com/stocks/xly.to

Not investment advice.